Immunome, Inc. (IMNM)
NASDAQ:IMNM
IMNM Stock Chart & Stats
$19.61
-$0.28(-2.60%)
At close: 4:00 PM EST
$19.61
-$0.28(-2.60%)
Day’s Range― - ―
52-Week Range$5.15 - $27.65
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.19M
Market Cap
$2.22B
Enterprise Value$1.07B
Total Cash (Recent Filing)$653.48M
Total Debt (Recent Filing)$3.85M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
May 07, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding113,133,200
10 Day Avg. Volume1,621,813
30 Day Avg. Volume1,194,750
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue154.64
Enterprise Value/Gross Profit-24.53
Enterprise Value/Ebitda-5.14
Forecast
1Y Price Target
$35.36Price Target Upside80.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.4
Revenue Forecast (FY)$9.83M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyLate-stage trial data for varegacestat showed substantially greater tumor shrinkage and improved disease control compared with the only approved therapy in desmoid tumors, suggesting the drug could reduce the need for surgery or chemotherapy and improve patient quality of life.
Pipeline Diversification And Early ValidationEarly proof-of-concept activity for the ROR1 antibody-drug conjugate IM-1021 and a clinical-ready radioligand expand development options and reduce reliance on a single program, increasing the potential for additional value drivers beyond the lead asset.
Regulatory And Commercial PathwayA planned NDA submission for varegacestat along with stated launch readiness positions the company to pursue regulatory approval and potential commercialization, which could unlock new revenue streams if regulators grant approval.
Bears Say
Cash Burn And Financing RiskNegative operating cash flow and a high cash burn rate create a limited cash runway and raise the likelihood of needing additional financing, which could delay programs or dilute existing shareholders.
Clinical-readout UncertaintySeveral important clinical readouts remain pending, creating uncertainty about program outcomes and the timing of potential regulatory or commercial milestones that investors expect.
Competitive Adoption In Community SettingsCompetitors' use of advanced patient-identification tools and active adverse-event management in community centers may make it harder for varegacestat to achieve broad community adoption, intensifying commercial competition.
Immunome News
IMNM FAQ
What was Immunome, Inc.’s price range in the past 12 months?
Immunome, Inc. lowest stock price was $5.15 and its highest was $27.65 in the past 12 months.
What is Immunome, Inc.’s market cap?
Immunome, Inc.’s market cap is $2.22B.
When is Immunome, Inc.’s upcoming earnings report date?
Immunome, Inc.’s upcoming earnings report date is May 07, 2026 which is in 39 days.
How were Immunome, Inc.’s earnings last quarter?
Immunome, Inc. released its earnings results on Mar 03, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.17.
Is Immunome, Inc. overvalued?
According to Wall Street analysts Immunome, Inc.’s price is currently Undervalued.
Does Immunome, Inc. pay dividends?
Immunome, Inc. does not currently pay dividends.
What is Immunome, Inc.’s EPS estimate?
Immunome, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Immunome, Inc. have?
Immunome, Inc. has 113,133,200 shares outstanding.
What happened to Immunome, Inc.’s price movement after its last earnings report?
Immunome, Inc. reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went up 4.55%.
Which hedge fund is a major shareholder of Immunome, Inc.?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.36 (80.32% Upside)
$35.36 (80.32% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 5.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.36%
12-Months-Change
Fundamentals
Return on Equity
-57.61%
Trailing 12-Months
Asset Growth
184.38%
Trailing 12-Months
Company Description
Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
IMNM Stock 12 Month Forecast
Average Price Target
$35.36
▲(80.32% Upside)
Technical Analysis
Ownership Overview
4.79% Insiders
30.19% Mutual Funds
32.89% Other Institutional Investors
21.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---